Alnylam Pharmaceuticals (ALNY) vs Takeda Pharmaceutical (TAK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Takeda Pharmaceutical (TAK) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, gaining 29.4% versus a loss of 50.2%. Over five years, TAK leads with a +31.3% price change compared with +7.7% for ALNY. Takeda Pharmaceutical is the larger company by market cap ($59.56 billion vs $30.74 billion), about 1.9 times the size.
On valuation, Alnylam Pharmaceuticals trades at a lower forward P/E (18.5x vs 35.2x for Takeda Pharmaceutical). Takeda Pharmaceutical pays a dividend yielding 1072.67%, while Alnylam Pharmaceuticals does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALNY | TAK |
|---|---|---|
| Share price | $229.70 | $18.65 |
| Market cap | $30.74B | $59.56B |
| 1-day change | +2.30% | +0.67% |
| YTD return | -43.54% | +18.79% |
| 1-year return | -50.18% | +29.42% |
| 5-year return | +7.66% | +31.35% |
| P/E ratio (TTM) | 38.74 | — |
| Forward P/E | 18.49 | 35.18 |
| EPS (TTM) | $5.93 | $-0.34 |
| Dividend yield | 0.00% | 1072.67% |
| Annual dividend | $0.00 | $200.00 |
| Revenue (latest FY) | $3.71B | — |
| Revenue growth (YoY) | +65.19% | — |
| Net income (latest FY) | $313.75M | — |
| Gross margin | 81.77% | — |
| Operating margin | 13.51% | — |
| Net margin | 8.45% | — |
| 52-week high | $495.55 | $19.10 |
| 52-week low | $197.81 | $12.99 |
| Distance from 52-week high | -53.65% | -2.38% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +61.57% | +17.78% |
| Average volume | 1.78M | 3.04M |
| Shares outstanding | 133.81M | 3.19B |
| Employees | 2,500 | 47,029 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TAK has outperformed ALNY by 79.6 percentage points over the past year.
- Takeda Pharmaceutical offers a meaningfully higher dividend yield (1072.67% vs 0.00%).
About Alnylam Pharmaceuticals
ALNY stock →Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees
About Takeda Pharmaceutical
TAK stock →Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees
ALNY vs TAK FAQ
Which is bigger, Alnylam Pharmaceuticals or Takeda Pharmaceutical?
Takeda Pharmaceutical (TAK) is larger, with a market capitalization of $59.56B compared with $30.74B for Alnylam Pharmaceuticals (ALNY).
Which stock has performed better over the past year, ALNY or TAK?
TAK returned +29.42% over the past 12 months, compared with -50.18% for ALNY (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Alnylam Pharmaceuticals or Takeda Pharmaceutical?
Takeda Pharmaceutical pays a dividend yielding 1072.67%, while Alnylam Pharmaceuticals does not currently pay a regular dividend.
Are Alnylam Pharmaceuticals and Takeda Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.